


EMBER-4 Study Design Overview

Key Eligibility Criteria

- ER+/HER2- EBC,
- Received 2 to 5 years of adjuvant ET with
- an increased risk of recurrence - measured by degree of spreading to regional lymph nodes:
 - a. $\geq N2$: ≥ 4 positive axillary lymph nodes (ALN)
 - b. $N1$: 1-3 ALN with ≥ 1 of the below:
 - Histologic grade 3
 - Tumor size ≥ 5 cm
 - Tumor size ≥ 2 cm but < 5 cm + grade 2
 - c. $N0$: No ALN with 1 of the below:
 - Tumor size ≥ 5 cm
 - Tumor size ≥ 2 cm but < 5 cm + grade 3



Note: ICF may be consented 90 days prior to visit 1 but screening period starts -28 day from visit 1.